The Pharma Data

SEPTEMBER 29, 2020

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas.

Structure Based Drug Design (SBDD) 52

Structure Based Drug Design (SBDD) Small Molecule Clinical Trials Pharma Companies 52

Dark Matter Blog

JUNE 21, 2023

Since our company’s founding in 2015, we have taken the long view and been singularly focused on building an extremely flexible and broadly applicable platform that can develop a host of RNA‑targeted small molecules (rSMs) to deliver precision medicines for dozens of targets that have been out of reach for conventional approaches.

Small Molecule 52

Small Molecule RNA Pharma Companies Science 52

Drug Discovery World

JANUARY 3, 2023

In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Most major pharma companies operate DEL platforms, and several service providers offer DEL capabilities to companies that outsource their DEL activities.

DNA 130

DNA Targeted Protein Degradation Small Molecule Pharma Companies 130

The Pharma Data

OCTOBER 14, 2020

Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. Talking Medicine uses advanced AI to provide pharmaceutical companies with real-time data intelligence. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals DNA 52